MG
RADX

Marex Group’s Radiopharm Theranostics RADX Stock Holding History

Marex Group’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,285
Closed -$53.7K – 1282
2025
Q4 		$53.7K Buy
+10,285
New +$54.8K ﹤0.01% 931

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Marex Group's RADX Position: Q1 2026 in Review

Marex Group sold out of Radiopharm Theranostics (RADX) in Q1 2026, closing a stake of 10,285 shares — an estimated $53.7K sold.

Marex Group first reported a position in RADX in Q4 2025 and held it in 1 quarter. The position peaked at $53.7K in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • Marex Group reported no remaining Radiopharm Theranostics position as of Q1 2026 after selling out during the quarter.
  • Marex Group sold 10,285 Radiopharm Theranostics shares in Q1 2026, an estimated $53.7K.
  • Marex Group first reported a position in Radiopharm Theranostics in Q4 2025 and held it in 1 quarter.
  • Marex Group's Radiopharm Theranostics position peaked at $53.7K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.